The demand for new strategies in downstream processing of biopharmaceutical plasmid DNA has increased in response to the importance of nucleic acids as active pharmaceutical ingredients (API) in gene therapy and genetic vaccination. Led by the problematic usage of animal-derived proteins for producing reagents of clinical applications, we present an opportunity of removing RNA prior to chromatographic steps by using a recombinant RNase Ba (barnase of Bacillus amyloliquefaciens) as an alternative to bovine RNase A. An expression vector for RNase Ba production was constructed enabling periplasmic localization of the recombinant protein. Cultivation of the RNase-producing clone showed stable activity (3.6 kU mL(-1) during stationary phase) throughout the cultivation process. After purification the RNase activity was tested and compared to that of commercially available RNase A. RNase Ba showed no DNase activity even after prolonged incubation with plasmid DNA. Thus, it is a suitable substitute for bovine RNase A in pharmaceutical purification processes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/bp050417e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region.
Eur J Surg Oncol
January 2025
Institute of Oncology Ljubljana, Slovenia; Faculty of Health Sciences, University of Ljubljana, Slovenia. Electronic address:
Introduction: In the treatment of cancer, immunomodulatory approaches are developed to support the organism in fighting cancer or to enhance the immunomodulatory effects of local ablative techniques. To this end, we conducted an interventional, open-label, single-arm Phase I trial to evaluate the safety and tolerability of intratumoral phIL12 plasmid DNA gene electrotransfer as primary objectives.
Methods: The study was dose-escalating with 3 consecutive cohorts of 3 patients per phIL12 dose level (0.
Melittin suppresses ovarian cancer growth by regulating SREBP1-mediated lipid metabolism.
Phytomedicine
January 2025
School of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
Background: Melittin, a major peptide component of bee venom, has demonstrated promising anti-cancer activity across various preclinical cell models, making it a potential candidate for cancer therapy. However, its molecular mechanisms, particularly in ovarian cancer, remain largely unexplored. Ovarian cancer is a life-threatening gynecological malignancy with poor clinical outcomes and limited treatment options.
View Article and Find Full Text PDFA cross-species inducible system for enhanced protein expression and multiplexed metabolic pathway fine-tuning in bacteria.
Nucleic Acids Res
January 2025
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, NO.1800, Lihu avenue, Wuxi 214122, China.
Inducible systems are crucial to metabolic engineering and synthetic biology, enabling organisms that function as biosensors and produce valuable compounds. However, almost all inducible systems are strain-specific, limiting comparative analyses and applications across strains rapidly. This study designed and presented a robust workflow for developing the cross-species inducible system.
View Article and Find Full Text PDFThe pathway to resolve dimeric forms distinguishes plasmids from megaplasmids in Enterobacteriaceae.
Nucleic Acids Res
January 2025
Laboratoire de Microbiologie et de Génétique Moléculaires, Centre de Biologie Intégrative, Université de Toulouse, CNRS, 165 Rue Marianne Grunberg-Manago, campus Paul Sabatier, 118, route de Narbonne, 31062, Toulouse Cedex, France.
Bacterial genomes contain a plethora of secondary replicons of divergent size. Circular replicons must carry a system for resolving dimeric forms, resulting from recombination between sister copies. These systems use site-specific recombinases.
View Article and Find Full Text PDFRetraction Notice: "MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization".
Int J Immunopathol Pharmacol
January 2025
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!